The activation of OR51E1 causes growth suppression of human prostate cancer cells

Oncotarget

Volumn 7, Issue 30, 2016, Pages 48231-48249

  Maßberg, Désirée ^a   Jovancevic, Nikolina ^a   Offermann, Anne ^b   Simon, Annika ^a   Baniahmad, Aria ^c   Perner, Sven ^b   Pungsrinont, Thanakorn ^c   Luko, Katarina ^c   Philippou, Stathis ^d   Ubrig, Burkhard ^d   Heiland, Markus ^d   Weber, Lea ^a   Altmüller, Janine ^e   Becker, Christian ^e   Gisselmann, Günter ^a   Gelis, Lian ^a,f   Hatt, Hanns ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Pathology of the University Hospital of Luebeck and Leibniz Research Center Borstel   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d Augusta Kranken Anstalt   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f BAYER PHARMA AG   (Germany)

Author keywords

Androgen receptor; Cellular senescence; OR51E1; Proliferation; Prostate cancer

Indexed keywords

AMYL BUTYRATE; ANDROGEN RECEPTOR; BUTYRIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; NONANOIC ACID; NONANOL; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR 2; PROTEIN KINASE; RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; OR51E1 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL AGING; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MALE; PLASMID; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SEQUENCE; WESTERN BLOTTING; BIOSYNTHESIS; CASTRATION RESISTANT PROSTATE CANCER; DISEASE EXACERBATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELLULAR SENESCENCE; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84982803598     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10197     Document Type: Article

References (85)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32:5501-5511.
3. Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 2015; 6:35542-35555. doi: 10.18632/oncotarget.4689.
4. Calabrese EJ. Androgens: biphasic dose responses. Crit Rev Toxicol. 2001; 31:517-522.
5. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996; 93:11802-11807.
6. Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010; 70:1600-1607.
7. Niu Y, Altuwaijri S, Lai K, Wu C, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A. 2008; 105:12182-12187.
8. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999; 59:4161-4164.
9. Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, Esmaeili M, Foller S, Petersen I, Grimm M, Baniahmad A. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014; 13:214.
10. Wei W, Hemmer RM, Sedivy JM. Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol. 2001; 21:6748-6757.
11. Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol. 2002; 34:1401-1414.
12. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005; 7:816-823.
13. Campisi J, Di d'Adda Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740.
14. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001; 11:S27-31.
15. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004; 23:2919-2933.
16. Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV. Androgen receptor drives cellular senescence. PLoS ONE. 2012; 7:e31052.
17. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004; 25:276-308.
18. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002; 277:7076-7085.
19. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem. 2005; 280:11583-11589.
20. Xie Y, Wolff DW, Lin M, Tu Y. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol Pharmacol. 2007; 72:73-85.
21. Zhu M, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008; 15:841-849.
22. Patel N, Itakura T, Jeong S, Liao C, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS ONE. 2015; 10:e0117758.
23. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000; 60:6568-6572.
24. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP. D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun. 2004; 322:239-249.
25. Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006; 9:56-61.
26. Fuessel S, Weigle B, Schmidt U, Baretton G, Koch R, Bachmann M, Rieber EP, Wirth MP, Meye A. Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. Cancer Lett. 2006; 236:95-104.
27. Weng J, Wang J, Hu X, Wang F, Ittmann M, Liu M. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer. 2006; 118:1471-1480.
28. Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS ONE. 2013; 8:e55368.
29. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G, Demoulin J, Giandomenico V. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol. 2009; 22:261-272.
30. Cui T, Tsolakis AV, Li S, Cunningham JL, Lind T, Öberg K, Giandomenico V. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. Eur J Endocrinol. 2013; 168:253-261.
31. Giandomenico V, Cui T, Grimelius L, Öberg K, Pelosi G, Tsolakis AV. Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids. J Mol Endocrinol. 2013; 51:277-286.
32. Parmentier M, Libert F, Schurmans S, Schiffmann S, Lefort A, Eggerickx D, Ledent C, Mollereau C, Gérard C, Perret J. Expression of members of the putative olfactory receptor gene family in mammalian germ cells. Nature. 1992; 355:453-455.
33. Feingold EA, Penny LA, Nienhuis AW, Forget BG. An olfactory receptor gene is located in the extended human beta-globin gene cluster and is expressed in erythroid cells. Genomics. 1999; 61:15-23.
34. Gaudin JC, Breuils L, Haertlé T. New GPCRs from a human lingual cDNA library. Chem Senses. 2001; 26:1157-1166.
35. Kang N, Koo J. Olfactory receptors in non-chemosensory tissues. BMB Rep. 2012; 45:612-622.
36. Zhang X, Bedigian AV, Wang W, Eggert US. G proteincoupled receptors participate in cytokinesis. Cytoskeleton (Hoboken). 2012; 69:810-818.
37. Flegel C, Schöbel N, Altmüller J, Becker C, Tannapfel A, Hatt H, Gisselmann G. RNA-Seq Analysis of Human Trigeminal and Dorsal Root Ganglia with a Focus on Chemoreceptors. PLoS ONE. 2015; 10:e0128951.
38. Flegel C, Vogel F, Hofreuter A, Schreiner BS, Osthold S, Veitinger S, Becker C, Brockmeyer NH, Muschol M, Wennemuth G, Altmüller J, Hatt H, Gisselmann G. Characterization of the olfactory receptors expressed in human spermatozoa. frontiers in Molecular Biosciences. 2015.
39. La Cruz O de, Blekhman R, Zhang X, Nicolae D, Firestein S, Gilad Y. A signature of evolutionary constraint on a subset of ectopically expressed olfactory receptor genes. Mol Biol Evol. 2009; 26:491-494.
40. Gu X, Ben-Shahar Y. Olfactory receptors in human airway epithelia. Methods Mol Biol. 2013; 1003:161-169.
41. Spehr M, Gisselmann G, Poplawski A, Riffell JA, Wetzel CH, Zimmer RK, Hatt H. Identification of a testicular odorant receptor mediating human sperm chemotaxis. Science. 2003; 299:2054-2058.
42. Veitinger T, Riffell JR, Veitinger S, Nascimento JM, Triller A, Chandsawangbhuwana C, Schwane K, Geerts A, Wunder F, Berns MW, Neuhaus EM, Zimmer RK, Spehr M et al. Chemosensory Ca2+ dynamics correlate with diverse behavioral phenotypes in human sperm. J Biol Chem. 2011; 286:17311-17325.
43. Braun T, Voland P, Kunz L, Prinz C, Gratzl M. Enterochromaffin cells of the human gut: sensors for spices and odorants. Gastroenterology. 2007; 132:1890-1901.
44. Busse D, Kudella P, Grüning N, Gisselmann G, Ständer S, Luger T, Jacobsen F, Steinsträßer L, Paus R, Gkogkolou P, Böhm M, Hatt H, Benecke H. A synthetic sandalwood odorant induces wound-healing processes in human keratinocytes via the olfactory receptor OR2AT4. J Invest Dermatol. 2014; 134:2823-2832.
45. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem. 2009; 284:16218-16225.
46. Maßberg D, Simon A, Häussinger D, Keitel V, Gisselmann G, Conrad H, Hatt H. Monoterpene (-)-citronellal affects hepatocarcinoma cell signaling via an olfactory receptor. Arch Biochem Biophys. 2015; 566:100-109.
47. Spehr J, Gelis L, Osterloh M, Oberland S, Hatt H, Spehr M, Neuhaus EM. G protein-coupled receptor signaling via Src kinase induces endogenous human transient receptor potential vanilloid type 6 (TRPV6) channel activation. J Biol Chem. 2011; 286:13184-13192.
48. Wiese H, Gelis L, Wiese S, Reichenbach C, Jovancevic N, Osterloh M, Meyer HE, Neuhaus EM, Hatt HH, Radziwill G, Warscheid B. Quantitative phosphoproteomics reveals the protein tyrosine kinase Pyk2 as a central effector of olfactory receptor signaling in prostate cancer cells. Biochim Biophys Acta. 2015; 1854:632-640.
49. Sanz G, Leray I, Dewaele A, Sobilo J, Lerondel S, Bouet S, Grébert D, Monnerie R, Pajot-Augy E, Mir LM. Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation. PLoS ONE. 2014; 9:e85110.
50. Rodriguez M, Luo W, Weng J, Zeng L, Yi Z, Siwko S, Liu M. PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis. 2014; 3:e114.
51. Saito H, Chi Q, Zhuang H, Matsunami H, Mainland JD. Odor coding by a Mammalian receptor repertoire. Sci Signal. 2009; 2:ra9.
52. Protopopov AI, Li J, Winberg G, Gizatullin RZ, Kashuba VI, Klein G, Zabarovsky ER. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med. 2002; 4:397-406.
53. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H. RTP family members induce functional expression of mammalian odorant receptors. Cell. 2004; 119:679-691.
54. Hessenkemper W, Roediger J, Bartsch S, Houtsmuller AB, van Royen ME, Petersen I, Grimm M, Baniahmad A. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Mol Endocrinol. 2014; 28:1831-1840.
55. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25:1105-1111.
56. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28:511-515.
57. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012; 7:562-578.
58. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinformatics. 2013; 14:178-192.
59. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9:671-675.
60. Moehren U, Papaioannou M, Reeb CA, Hong W, Baniahmad A. Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol. 2007; 21:1039-1048.
61. Jansson KH, Lynch JE, Lepori-Bui N, Czymmek KJ, Duncan RL, Sikes RA. Overexpression of the VSSCassociated CAM, β-2, enhances LNCaP cell metastasis associated behavior. Prostate. 2012; 72:1080-1092.
62. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92:9363-9367.
63. Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet. 2013; 29:569-574.
64. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985; 45:3663-3667.
65. Tuteja N. Signaling through G protein coupled receptors. Plant Signal Behav. 2009; 4:942-947.
66. Gelis L, Wolf S, Hatt H, Neuhaus EM, Gerwert K. Prediction of a ligand-binding niche within a human olfactory receptor by combining site-directed mutagenesis with dynamic homology modeling. Angew Chem Int Ed Engl. 2012; 51:1274-1278.
67. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989; 49:3474-3481.
68. Taub JS, Guo R, Leeb-Lundberg LMF, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003; 63:2037-2041.
69. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1:944-949.
70. Wang J, Weng J, Cai Y, Penland R, Liu M, Ittmann M. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 2006; 66:847-857.
71. Heng HHQ, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genomecentric perspective. J Cell Physiol. 2009; 220:538-547.
72. Gorlov IP, Byun J, Zhao H, Logothetis CJ, Gorlova OY. Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. J Bioinform Comput Biol. 2012; 10:1241013.
73. Loesch M, Zhi H, Hou S, Qi X, Li R, Basir Z, Iftner T, Cuenda A, Chen G. p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem. 2010; 285:15149-15158.
74. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001; 81:807-869.
75. Xing J, Ginty DD, Greenberg ME. Coupling of the RASMAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science. 1996; 273:959-963.
76. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogenand stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998; 17:4426-4441.
77. Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene. 2001; 20:1601-1606.
78. Xu Y, Li N, Xiang R, Sun P. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogeneinduced senescence. Trends Biochem Sci. 2014; 39:268-276.
79. Alemany R, Perona JS, Sánchez-Dominguez JM, Montero E, Cañizares J, Bressani R, Escribá PV, Ruiz-Gutierrez V. G protein-coupled receptor systems and their lipid environment in health disorders during aging. Biochim Biophys Acta. 2007; 1768:964-975.
80. Martin B, Pfeuffer M, Schrezenmeir J. Mediumchain triglycerides. International Dairy Journal. 2006; 16:1374-1382.
81. Costa CG, Dorland L, Holwerda U, Almeida IT de, Poll-The BT, Jakobs C, Duran M. Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid beta-oxidation disorders. Clin Chem. 1998; 44:463-471.
82. Narayanan A, Baskaran SA, Amalaradjou MAR, Venkitanarayanan K. Anticarcinogenic properties of medium chain fatty acids on human colorectal, skin and breast cancer cells in vitro. Int J Mol Sci. 2015; 16:5014-5027.
83. Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014; 5:7217-7259. doi: 10.18632/oncotarget.2406.
84. Schrantz N, da Silva Correia J, Fowler B, Ge Q, Sun Z, Bokoch GM. Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J Biol Chem. 2004; 279:1922-1931.
85. Liu J, Shimizu K, Kondo R. Anti-androgenic activity of fatty acids. Chem Biodivers. 2009; 6:503-512.